Treasury COINS Act Proposal Brings Biotech into Outbound Investment Restrictions

As a trade association representing Nebraska’s bioscience sector, we work every day to ensure this part of our state’s economy continues to grow and thrive. Recently, the United States Department of Treasury (Treasury) proposed a rule to implement the Comprehensive Outbound Investment National Security (COINS) Act, passed in 2025, which could negatively affect the sector.

Released October 22, 2026, the Treasury proposal would expand the existing Outbound Investment Security Program in the COINS Act, which prohibits certain investments and requires notification of others involving sensitive technologies. Treasury’s stated goal with the proposed rule is to prevent U.S. capital and associated benefits from advancing foreign adversaries’ military, intelligence and surveillance capabilities. Biotechnology was not among the five technology sectors expressly listed in the law. Treasury is using its discretionary authority to add it with the rule – a consequential decision for an industry built on international investment and scientific collaboration. 

While it would be ideal if every new scientific idea and breakthrough happened right here in the United States, that simply is not the case. Scientific innovation and discovery are being done around the world, including in China. By keeping these global channels open for partnerships and exchanging research between United States biopharmaceutical companies, we multiply the chances of developing new and innovative lifesaving medicines through this shared effort. However, the proposed COINS Act rule could make it difficult, or even impossible for United States biopharmaceutical companies to partner with Chinese companies to develop innovative medicines for American patients.

Millions of patients in the United States and Nebraska rely on the international partnerships that allow them to access the most innovative medicines and treatments available. Limiting our ability to work across borders to ensure patients here have access to new medicines would undermine not only our national security, but our economic competitiveness.

Bio Nebraska believes in maintaining the country’s national security; however, Bio Nebraska does not agree with the overly broad approach represented by the COINS Act proposed rule and feels it could be detrimental to maintaining America’s competitive advantage.